| Christopher Mark Pogodzinski, MD | |
|
4059 Jandy Blvd Ste 103, Nazareth, PA 18064-8893 | |
| (484) 503-6450 | |
| (484) 503-6445 |
| Full Name | Christopher Mark Pogodzinski |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 32 Years |
| Location | 4059 Jandy Blvd Ste 103, Nazareth, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124025952 | NPI | - | NPPES |
| 1748150 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD066347L (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Luke's Hospital Bethlehem | Bethlehem, PA | Hospital |
| St Luke's Hospital - Anderson Campus | Easton, PA | Hospital |
| St Luke's Warren Hospital | Phillipsburg, NJ | Hospital |
| Lehigh Valley Hospital | Allentown, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| St Luke's Physician Group Inc | 6709798333 | 1739 |
News Archive
Theravance, Inc. (NASDAQ: THRX) and Astellas Pharma US, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved VIBATIV™ (telavancin) for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, driven primarily by the launch and uptake of Human Genome Sciences/GlaxoSmithKline's Benlysta, the systemic lupus erythematosus (SLE) drug market will quadruple from about $400 million in 2009 to more than $1.6 billion in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
A recent study from the University of Eastern Finland in collaboration with Deakin University, Australia, shows that recurrent major depressive disorder (MDD) in men is associated with lower bone density. The use of antidepressants was also associated with lower bone mineral density (BMD), but this association was dependent on the person's weight and site of bone measurement.
Metabolic syndrome affects nearly 30 percent of the U.S. population, and increases the risk for type 2 diabetes, heart disease and stroke. But lifestyle interventions such as adopting a healthy diet and increasing physical exercise are difficult to maintain and, even when combined with medication, are often insufficient to fully manage the disease.
A moderate level of aerobic fitness can significantly reduce stroke risk for men and women, according to a large, long-running study presented at the American Stroke Association's International Stroke Conference 2008.
› Verified 9 days ago
| Entity Name | St Lukes Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700984622 PECOS PAC ID: 6709798333 Enrollment ID: O20040226000062 |
News Archive
Theravance, Inc. (NASDAQ: THRX) and Astellas Pharma US, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved VIBATIV™ (telavancin) for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, driven primarily by the launch and uptake of Human Genome Sciences/GlaxoSmithKline's Benlysta, the systemic lupus erythematosus (SLE) drug market will quadruple from about $400 million in 2009 to more than $1.6 billion in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
A recent study from the University of Eastern Finland in collaboration with Deakin University, Australia, shows that recurrent major depressive disorder (MDD) in men is associated with lower bone density. The use of antidepressants was also associated with lower bone mineral density (BMD), but this association was dependent on the person's weight and site of bone measurement.
Metabolic syndrome affects nearly 30 percent of the U.S. population, and increases the risk for type 2 diabetes, heart disease and stroke. But lifestyle interventions such as adopting a healthy diet and increasing physical exercise are difficult to maintain and, even when combined with medication, are often insufficient to fully manage the disease.
A moderate level of aerobic fitness can significantly reduce stroke risk for men and women, according to a large, long-running study presented at the American Stroke Association's International Stroke Conference 2008.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christopher Mark Pogodzinski, MD 4059 Jandy Blvd Ste 103, Nazareth, PA 18064-8893 Ph: (484) 503-6450 | Christopher Mark Pogodzinski, MD 4059 Jandy Blvd Ste 103, Nazareth, PA 18064-8893 Ph: (484) 503-6450 |
News Archive
Theravance, Inc. (NASDAQ: THRX) and Astellas Pharma US, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved VIBATIV™ (telavancin) for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, driven primarily by the launch and uptake of Human Genome Sciences/GlaxoSmithKline's Benlysta, the systemic lupus erythematosus (SLE) drug market will quadruple from about $400 million in 2009 to more than $1.6 billion in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
A recent study from the University of Eastern Finland in collaboration with Deakin University, Australia, shows that recurrent major depressive disorder (MDD) in men is associated with lower bone density. The use of antidepressants was also associated with lower bone mineral density (BMD), but this association was dependent on the person's weight and site of bone measurement.
Metabolic syndrome affects nearly 30 percent of the U.S. population, and increases the risk for type 2 diabetes, heart disease and stroke. But lifestyle interventions such as adopting a healthy diet and increasing physical exercise are difficult to maintain and, even when combined with medication, are often insufficient to fully manage the disease.
A moderate level of aerobic fitness can significantly reduce stroke risk for men and women, according to a large, long-running study presented at the American Stroke Association's International Stroke Conference 2008.
› Verified 9 days ago
Dr. Ryan T Smith, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 863 Nazareth Pike, Nazareth, PA 18064 Phone: 484-373-3260 Fax: 484-373-3128 | |
Videhi Patel, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 305 W North St, Nazareth, PA 18064 Phone: 610-759-2209 Fax: 610-759-2340 | |
Catherine Schrei Broadt, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4059 Jandy Blvd Ste 103, Nazareth, PA 18064 Phone: 610-759-1200 Fax: 610-759-4590 | |
Dr. Elspeth Black-carpenter, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4059 Jandy Blvd # 103, Nazareth, PA 18064 Phone: 484-503-6450 | |
Brianne Allerton, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 863 Nazareth Pike, Nazareth, PA 18064 Phone: 484-373-3260 Fax: 484-373-3128 | |
Dr. David Paul Zambo, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4263 Lonate Dr, Nazareth, PA 18064 Phone: 610-759-5501 Fax: 610-759-2216 |